• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Emergent BioSolutions to cut 400 jobs, focus on Narcan nasal spray

August 8, 2023 By Sean Whooley

Emergent Biosolutions Narcan
Narcan. [Image from Emergent BioSolutions]
Nasal Narcan spray maker Emergent BioSolutions (NSYE:EBS) announced a change in strategy and investment that affects 400 jobs.

The Gaithersburg, Maryland-based company decided to reduce investment in and de-emphasize focus on growth in its CDMO business. This results in a reduction of operations at the company’s Bayview facility in Baltimore.

Additionally, in response to changes in the volume of U.S. government procurements of medical countermeasures, the company intends to further reduce operations at its facility in Canton, Massachusetts. In turn, this results in a small reduction of operations at its drug product facility in Rockville, Maryland.

In total, the changes lead to a reduction of approximately 400 employees across all areas of the company. Emergent BioSolutions expects to see annualized savings of over $100 million when it fully implements the changes. It forecasts costs between $19 million and $21 million for the effort.

Going forward, Emergent BioSolutions plans to focus on its core products business: medical countermeasures and Narcan nasal spray. The FDA approved the over-the-counter Narcan spray in May. It expects to maintain a level of operations at Bayview and Canton to ramp up production in response to new demand.

“The actions we are taking will further strengthen our core products business and financial foundation,” said Emergent interim CEO Haywood Miller. “This will better align Emergent’s businesses with a focus on our core products and delivering for the needs of our customers. It will provide us with flexibility to respond to future customer demand while responsibly maintaining manufacturing infrastructure deemed critical to respond to public health threats.”

More on the changes at Emergent BioSolutions

As a result of the shift away from Emergent’s services business, it eliminated the role of chief operating officer. As a result, Adam Havey, who currently holds that role, is to leave the company on Sept. 30.

Bill Hartzel, SVP and head of bioservices, assumes responsibility for manufacturing operations. He also joins the executive management team, reporting to Miller.

Paul Williams, SVP of products, said the company’s focus rests in areas where it feels it can have a positive impact. Emergent BioSolutions remains committed to address public health threats, he added.

“Changes like these are never easy as they impact many of our colleagues,” said Miller. “I want to thank Adam for his more than 20 years of service to Emergent, and all those who are affected by these actions for their dedication and contributions. Emergent is committed to working with impacted employees to help transition them to new opportunities.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel, Pharmaceuticals Tagged With: Emergent BioSolutions

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS